

TITULO	REVISTA	FI	Q	DOI	Pubmed Id	UT (Unique WOS ID)
Safety and Immunogenicity of SARS-CoV-2 vaccines in people with HIV	AIDS	4,632	Q2	10.1097/QAD.0000000000003161	34999608	WOS:000772527800010
Analysis of the costs associated with the follow-up of HIV patients discontinuing antiretroviral treatment due to lack of effectiveness or unacceptable toxicity in Spain	FARMACIA HOSPITALARIA			10.7399/fh.13038	36520571	WOS:000877055300001
Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study	EUROPEAN JOURNAL OF HOSPITAL PHARMACY	2,537	Q3	10.1136/ejhpharm-2020-002374	33051194	WOS:000818827200007
Similar CD4/CD8 Ratio Recovery After Initiation of Dolutegravir Plus Lamivudine Versus Dolutegravir or Bictegravir-Based Three-Drug Regimens in Naive Adults With HIV	FRONTIERS IN IMMUNOLOGY	8,786	Q1	10.3389/fimmu.2022.873408	35432298	WOS:000788055700001
Metabolic-Related Outcomes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Adults With Human Immunodeficiency Virus (HIV): A Multicenter Prospective Cohort Study	CLINICAL INFECTIOUS DISEASES	20,999	D1	10.1093/cid/ciac621	35903910	WOS:000841953100001
Monoclonal antibody therapies in the management of SARS-CoV-2 infection	EXPERT OPINION ON INVESTIGATIONAL DRUGS	6,498	Q1	10.1080/13543784.2022.2030310	35164631	WOS:000755469900001
Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naive non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study	GASTROENTEROLOGIA Y HEPATOLOGIA	5,867	Q2	10.1016/j.gastrohep.2021.05.015	34129903	WOS:000807160600002